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Abstract 
Primary small cell carcinoma of the prostate (SCPCa) is a rare pathologic entity with 
unique clinical features and a poor prognosis. We present a case of a patient diagnosed 
with pure SCPCa treated with a combined chemo-radiotherapeutic approach. 
Pathological findings showed that the neoplastic cells exhibited positivity for 
pancytokeratin, synaptophysin, thyroid transcription factor-1 and CD56. Immunostaining 
for prostate-specific antigen was negative, while serum prostate-specific antigen was 
within normal limits. We review the available literature to gain additional information 
about diagnosis, treatment and prognosis of pure SCPCa. 
Introduction 
Small cell carcinoma of the prostate (SCPCa), also termed neuroendocrine SCPCa, was 
first described by Wenk et al. [1] in 1977. Its incidence has been estimated at slightly less 
than 2% of de novo prostate cancer [2]. Small cell carcinomas usually present together 
with adenocarcinomas. In some cases, neuroendocrine differentiation occurs sequentially, 
with an initial pattern of conventional adenocarcinoma, which thereafter presents with 
focal neuroendocrine differentiation while in recurrence after androgen deprivation 
therapy [3]. In approximately 35% of SCPCa cases, the histology is pure SCPCa [4]. 
The clinical phenotype of SCPCa may be distinguishable from that of typical 
adenocarcinoma by the common initial presentation of rapidly symptomatic, locally 
advanced or metastatic disease, occurring frequently with visceral and lytic bone 
metastases, marked prostatic enlargement and disproportionately low or absent prostate- 
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specific antigen (PSA) levels as well as resistance to androgen ablation. These tumors are 
highly aggressive, with a median survival of 9–10 months and a 5-year survival of less 
than 1% [5]. The most typical age at diagnosis is 61–70 years, although an age range from 
24 to 90 years has been reported [2]. Prostatic malignant neuroendocrine cells tend to 
produce ectopic peptides, with adrenocorticotropic hormone (ACTH) and calcitonin 
being detected most frequently in serum. Approximately 10% of small cell carcinoma 
cases present with paraneoplastic syndromes [2, 6]. 
The most common immunohistochemical markers used to diagnose SCPCa are 
neuron-specific enolase (NSE), chromogranin A (ChrA), synaptophysin (Syn), CD56 and 
thyroid transcription factor-1 (TTF-1). Serum ACTH, calcitonin, and parathyroid 
hormone levels may be elevated regardless of the presence of paraneoplastic syndromes. 
Tumor markers such as carcinoembryonic antigen (CEA) and cancer antigen 19-9 (Ca 
19-9) are also often elevated [3, 6]. 
PSA is a more complicated marker of the disease. Generally, in the case of 
adenocarcinoma, the disease burden is strongly correlated with the PSA level. However, 
in patients with mixed tumors or pure SCPCa, the neuroendocrine component does not 
secrete PSA and, therefore, does not contribute to an elevated PSA level, as PSA reflects 
the bulk and activity of the nonmalignant elements in the prostate [2]. 
Given the distinct pathologic and clinical features of the disease and using small cell 
carcinoma of the lung as a therapeutic model, the treatment for mixed or pure SCPCa 
consists mainly of a combined multidrug chemotherapy and radiation therapy to improve 
local control, with radical prostatectomy as an adjunctive therapy in selected cases [5, 7]. 
Chemotherapy regimens have been employed with a reported response rate of 60% 
without any durable complete remission [8]. 
We present a case of pure SCPCa treated with a combined chemo-radiotherapeutic 
approach. Written informed consent was obtained from the patient for the publication of 
this case report and any accompanying images. Moreover, we review the available 
literature to gain additional insight into the diagnosis, treatment, and prognosis of this 
disease. 
Case Report 
In May 2007, a 77-year-old man was referred to our hospital with symptoms of urinary retention 
and dysuria. His past medical history included cardiac insufficiency. On digital rectal examination, the 
prostate was homogeneously enlarged and diffusely firm. The serum PSA level was within the normal 
range (1.4 ng/ml; range: 0–4). He underwent an operation for phimosis, and a catheter was inserted into 
the urinary bladder. Two weeks after the surgery, the patient was admitted to the urology clinic with 
macroscopic hematuria and catheter occlusion. A transrectal needle biopsy disclosed a locally advanced, 
poorly differentiated SCPCa. Computer tomography (CT) of the pelvis showed an enlarged prostate 
with protrusion into the bladder, while a chest CT showed diffuse lung emphysematous microbullae. A 
bone scan was negative for metastases. The Ca 19-9 level was elevated (96 ng/ml; range: 1–37), while the 
CEA level was within normal limits. 
Microscopically, both lobes were diffusely infiltrated by small round neoplastic cells with scanty 
cytoplasm and a high nuclear to cytoplasmic ratio. The nuclei were hyperchromatic, finely granular with 
inconspicuous nucleoli (fig. 1). Perineural and neural invasion were focally identified. 
Immunohistochemically, the neoplastic cells exhibited positivity for pancytokeratin, Syn, TTF-1 and 
CD56 (fig. 2). Immunostaining for PSA was negative. The histopathological pattern as well as the 
presence of positive staining for neuroendocrine markers and the absence of pulmonary lesions  
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suggestive of primary pulmonary pathology were the basis for the diagnosis of pure primary SCPCa. 
The tumor was staged as T2cN0M0 (2002 American Joint Committee on Cancer (AJCC) Staging 
Criteria). 
The patient was admitted to the Radiation Therapy Department of the University Hospital of 
Ioannina in July 2007. Radiotherapy was given with 4 parallel opposed fields (box technique). The 
prostate and the regional lymph nodes were included in the irradiation fields. A linear accelerator  
(6 MV) was used. The daily dose was 1.8 Gy and the total dose was 63 Gy. In total, 35 fractions were 
given. After 45 Gy to the whole pelvis, a boost dose (18 Gy) to the primary site was applied using the 
shrinkage technique. Six chemotherapy cycles (carboplatin, 450 mg/AUC 5) were also administered 
every 21 days concomitantly and consequently to radiotherapy. The patient tolerated this treatment 
well, without any interruption due to acute side effects. 
The patient was asymptomatic 6 months after treatment. Serum PSA was within normal limits (0.2 
ng/ml), while Ca 19-9 remained elevated (69 ng/ml; range: 1–37). Serum SGOT, SGPT and LDH were 
also elevated. At that time, the patient underwent a chest CT scan because of intensive and irritative 
cough. The CT scan revealed an enlarged left hilum with lobular atelectasis as well as multiple nodular 
bilateral lung metastatic lesions. He was hospitalized because of dyspnea and died few weeks later, as his 
condition continued to deteriorate. The patient died 12 months after the initial diagnosis. 
Discussion 
SCPCa is rare, accounting for 0.5–2% of all prostatic malignancies [2, 3]. The prostate 
is one of the more common sites of extrapulmonary small cell carcinomas. 
Adenocarcinomatous elements are present concomitantly in at least half of cases, but 
prognosis does not appear to be affected by the presence of a non-small cell component 
as, after recognition of the small cell phenotype, in these cases, survival is less than 1.5 
years. Additionally, the small cell component may be multifocal and variably distributed 
through the prostate [3, 7, 9]. 
Most patients with SCPCa are symptomatic at diagnosis in comparison with patients 
with prostate adenocarcinoma alone. Signs and symptoms, in order of frequency, include 
obstructive, neurologic, and constitutional symptoms, followed by symptoms from 
paraneoplastic syndromes, bone pain, hydronephrosis, abdominal pain, hematochezia, 
and hematuria. These tumors have a propensity to metastasize distally to visceral organs, 
including the liver, bone, lungs, central nervous system, and pericardium, and regionally 
to the pelvic lymph nodes. The rectum and bladder can be invaded due to local tumor 
infiltration [2]. 
The histologic origin of SCPCa remains controversial. Several theories have been 
proposed over the years. The initial hypothesis was that SCPCa is derived from the neural 
crest line/amine precursor uptake and decarboxylase cell system, now called 
neuroendocrine system, a cell lineage that is different from prostatic epithelium [1]. 
Another theory favors a malignant transformation of normal prostatic neuroendocrine 
cells. Based on the observation that SCPCa sometimes coexists with adenocarcinoma, it 
was postulated that SCPCa is the product of a final dedifferentiation of the typical 
adenocarcinoma according to the model of divergent differentiation [10]. Coexpression 
of PSA in neuroendocrine cells was viewed as supporting evidence for the prostatic 
epithelial origin of these cells. Nevertheless, the cells seem to represent postmitotic cells, a 
fact that makes it unlikely that these cells suddenly start to proliferate and become a 
highly aggressive small cell carcinoma. Finally, a recent theory proposes a direct origin 
from a multipotential prostatic epithelial stem cell for SCPCa, based on the lack of 
immunohistologic characteristics typical of the usual prostatic epithelial cell (PSA  
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expression and androgen receptor positivity) and the extremely high MIB-1 labeling 
index clearly exceeding that of even dedifferentiated adenocarcinomas [11]. 
The prostatic neuroendocrine cells have regulatory functions and are capable of 
producing and releasing a wide variety of secretory products like serotonin and various 
peptides, including the chromogranins, peptides of the calcitonin families, ACTH, the 
parathormone-related protein, thyroid-stimulating hormone-like peptides, human 
choriogonadotropin-like peptides, somatostatin, glucagons, CEA, and the bombesin-like 
peptides [3, 6]. 
NSE, ChrA, TTF-1 and Syn are considered representative neuroendocrine tissue 
markers that are used in the pathologic diagnosis of SCPCa in addition to a lack of 
androgen receptor positivity and a lack of PSA [11]. It has also been reported that 
neuroendocrine SCPCa cells showing an aggressive phenotype exhibit intense staining of 
vascular endothelial growth factor (VEGF) [12]. 
The measurement of serum neuroendocrine markers should be useful for diagnosing 
and monitoring the patients’ clinical course, as this constitutes a representative indicator 
and an objective measure of the neuroendocrine differentiation, reflecting not only the 
primary tumor cell population but also its associated metastases. NSE and ChrA have 
been demonstrated as the main serum neuroendocrine markers for the clinical evaluation 
of SCPCa [6]. Additionally, it has been reported that patients who present with a low 
serum albumin level and a high serum LDH level at the time of initial diagnosis appear to 
have inferior survival [5]. 
Because of the rarity of pure SCPCa, most of our knowledge concerning its diagnosis, 
treatment and prognosis has been gained from a few single-institution reviews and case 
reports. Therefore, it is impossible to draw definitive conclusions regarding the most 
effective treatment of this disease. The published studies assessed cases of pure SCPCa 
together with cases where SCPCa coexists with adenocarcinoma. The existing and mostly 
single-institution experience with SCPCa and an analysis of the pure SCPCa cases are 
summarized in table 1. 
The role of hormonal therapy in small cell carcinoma remains controversial. In the 
setting of mixed histologies, hormonal therapy (by orchiectomy, gonadotropin-releasing 
agonists, or antagonists with the early addition of antiandrogens) should be used 
according to stage and treatment regimens. For localized disease, hormonal therapy could 
be used as an adjunct to radiation therapy. The timing (neoadjuvant or adjuvant) and 
duration of hormone ablation in those patients are uncertain. Nonetheless, it should not 
be used as a sole therapy. For metastatic disease, long-term hormonal therapy should be 
combined with chemotherapy [2, 7]. In cases of pure SCPCa, hormonal therapy is not 
recommended, as the prostatic neuroendocrine cells are deprived of androgen receptors 
[3]. 
Whether the androgen ablation therapy should be continued or not in patients with 
adenocarcinoma whose tumors undergo neuroendocrine transdifferentiation is a crucial 
matter. Considering that prolonged hormonal ablation therapy may enhance the selection 
and progression of neuroendocrine differentiated, androgen-independent tumor cells 
through processes of transdifferentiation or clonal selection [6], in combination with the 
antiandrogen withdrawal effect, it is recommended that the antiandrogens are 
discontinued before initiation of chemotherapy.  
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According to small cell lung carcinoma treatment experience, cisplatin and etoposide 
are the most commonly recommended agents. A recent phase II trial advocated that the 
addition of doxorubicin to this regimen caused higher toxicity related to the patients’ 
survival outcome [8]. Cyclophosphamide, vincristine, taxanes and ifosfamide have also 
been added to cisplatin in various combinations [2, 13]. Carboplatin combined with 
etoposide or taxanes has also been administered instead of cisplatin. Regarding 
irradiation, no exact guidelines for total dose and irradiation volume have been given. 
Because of the disease propensity for local and pelvic lymph node relapse, the treatment 
volume should include the pelvic lymph nodes with a dose between 45 and 55 Gy (daily 
dose 1.8 Gy), followed by a boost to the prostate volume reaching in some studies a total 
dose of 72 Gy [7]. 
Although in SCPCa locoregional treatment is secondary to systemic therapy, in cases 
of localized or early SCPCa, several studies suggest that surgical resection with or without 
external beam radiotherapy should be evaluated further as a treatment strategy for 
selected patients with nonmetastatic SCPCa, as it may provide better local control and a 
potential survival benefit when combined with systemic therapy compared with systemic 
therapy alone [5, 14]. 
In some cases, the diagnosis of SCPCa will be incidental to a coexisting 
adenocarcinoma upon pathological examination of a prostatectomy specimen. Adjuvant 
chemotherapy – at least 4 cycles of cisplatin and etoposide – should be added to these 
patients [2], while adjuvant radiotherapy is implemented at the discretion of the treating 
physician, based on adverse pathologic features such as involved surgical margins and/or 
extracapsular extension (pT3a) [7]. 
Metastatic disease is treated with chemotherapy. Radiation therapy could also have a 
role in the treatment of patients with SCPCa and metastases. Its role is palliative, as it may 
control local symptoms such as complications of brain and bone metastases. 
Transurethral resection of the prostate may be considered for cases with obstructive 
voiding symptoms that do not respond to chemotherapy and pharmacologic 
interventions. 
Recently, the neuroendocrine cells became a therapeutic target, which opens additional 
options for patients with SCPCa. Agents, like somatostatin analogues, neuropeptide-like 
serotonin and bombesin antagonists, or inflammatory cytokines, like interleukin-6, are 
under investigation in clinical and laboratory settings. However, trials using somatostatin 
analogues not only for SCPCa but also for hormone refractory prostate cancer with or 
without metastases have attained some success without major adverse effects [15]. The 
expression of the angiogenic factors VEGF and TGF-A in neuroendocrine SCPCa cells 
may also be used in the diagnosis, follow-up and targeting of specific molecular sites. 
Additionally, in hormone refractory prostate cell lines, it has been found that VEGF-C 
promotes survival of cancer cells under oxidative stress by the activation of mammalian 
target of rapamycin and Akt [12] – a mechanism that could also potentially serve as a 
novel therapeutic target.  
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Conclusion 
SCPCa presents an aggressive tumor histology that is associated with a high disease-
specific mortality. For patients with localized disease, a benefit of the application of local 
treatment modalities like radiation therapy, in combination with chemotherapy with or 
without hormonal therapy, seems to be acceptable. Further research may lead to advances 
in the understanding of the neuroendocrine differentiation in prostate cancer, potential 
integration of treatment modalities and exploration of novel therapeutic targets that 
would be translated in improved clinical outcome. 
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Table 1. Major single-institution reviews of SCPCa and analysis of pure SCPCa cases 
Study Inclusion 
period  
SCPCa 
n 
Pure  
SCPCa 
n (%) 
Stage 
III/IV 
 
PSA, ng/ml 
median (range) 
Elevated 
PSA 
Immunostaining Chemo-
therapy 
Additional therapy   OS, months 
median (range) 
Amato  
1992 [13] 
–  21  13 (62)  100%  –  7%  –  100%  ADT: 15 (71%)  9.4 (1–25) 
Oesterling 
1992 [10] 
1960– 
1990 
27  18 (67)  26 (96%)  –  –  NSE (+): 100% 
PSA (+): 0% 
7% ADT:  25  (71%) 
EBRT: 15 (56%) 
Surgery: 2 (7%) 
17.1 (2–90) 
non pure:  
3/9 (33%) 
non pure:  
56.4 (3.5–146) 
 non  pure: 
NSE (+): 0% 
Syn (+): 0% 
ChrA (+): 0% 
PSA (+): 61.8% 
 non  pure: 
ADT: 3/9 (33%) 
EBRT: 3/9 (33%) 
Surgery: 3/9 (33%) 
non pure:  
12 
Helpap  
1999 [11] 
1994– 
1998 
19 10  (53) 
pure:  
5/10 (50%) 
pure: 
7.1 (0.9–23.6) 
– pure: 
NSE (+): 83% 
Syn (+): 61% 
ChrA (+): 25% 
PSA (+): 0% 
0% pure: 
ADT: 3/10 (30%) 
Surgery: 1/10 (10%) 
pure:  
7.7 (2–12) 
Sella  
2000 [9]  
1995– 
1999 
18  6 (33)  100  1.6 (0–9.5)  0%  NSE (+): 14/16 (88%) 
[NSE (+) in pure: 6/6] 
ChrA (+): 12/16 (75%) 
[ChrA (+) in pure: 5/6] 
67% prior: 
ADT (100%) 
6.7 (0.02–29.6) 
Papandreou 
2002 [8] 
1992– 
1999 
36  24 (67)  stage IV:  
32 (89%) 
1.5 (0.05–283)  11  
(31%) 
ChrA (+): 20/29 (69%) 
Syn (+): 20/27 (74%) 
100% prior: 
ADT: 29 (81%) 
EBRT: 16 (44%) 
10.5 (7.5–14.3)  
Asmis  
2006 [14] 
1991– 
2002 
10  5 (50)  8 (80%)  –  –  –  80%  ADT: 3 (30%) 
EBRT: 8 (80%) 
9.5 (2–16) 
Spiess 
2007 [5] 
1985– 
2005 
83  30 (36)  stage IV:  
62 (75%) 
10 (0.9–603)  0%  –  76  
(92%) 
ADT: 39 (47%) 
EBRT: 6 (7%) 
surgery: 3 (4%) 
13.1 (10.7–17.1) 
ADT = Androgen deprivation therapy; PSA = prostate-specific antigen; EBRT = external beam radiotherapy; NSE = neuron-specific enolase; ChrA = chromogranin A; 
Syn = synaptophysin. 
 
 
 
  
Case Rep Oncol 2011;4:88–95 
DOI: 10.1159/000324717 
Published online: 
February 16, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
94
 
Fig. 1. HE staining (original magnification ×400). 
 
 
 
Fig. 2. Immunostaining for CD56 (original magnification ×400). 
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